Replies to post #154409 on Biotech Values

[p3analyze]

I dont understand why you bring up Tdm1. It is trastzmb plus endocytotic toxin delivery. of course 3 (her2 signaling blockade+ adcc antibody dependent cell mediated cytotoxicity + ADC antibody drug conjugate) is
better than 2 without ADC. the Adcc component of tmab has to be there as blocking her 2 signaling via tki alone could not achieve the same effect as tmab.

Where else will the backbone antigen PAP of Provenge be expressed after the prostate was out besides PCa cells? Do you not agree an overexpression of target antigen in tumor cell presents a therapeutic window of selective tumor cell killing which is next best to a tumor exclusive antigen.

I do agree perhaps targeting antigen alone may not be sufficient if normal protein epitome coexists to prevent self recognition. So perhaps stimuvax does need ipi or antipd1.